🇺🇸 FDA
Patent

US 6743791

Heterocyclic inhibitors of ERK2 and uses thereof

expired A61PA61P1/16A61P11/00

Quick answer

US patent 6743791 (Heterocyclic inhibitors of ERK2 and uses thereof) held by Vertex Pharmaceuticals Incorporated expires Mon May 27 2024 00:00:00 GMT+0000 (Coordinated Universal Time). Status: expired.

Key facts

Applicant
Vertex Pharmaceuticals Incorporated
Grant date
Tue Jun 01 2004 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 27 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
57
CPC classes
A61P, A61P1/16, A61P11/00, A61P17/06, A61P19/00